rs10769203 - TRIM5
Magnitude 4.5 · 1 study on file
Reported associations
-
Genetic Prediction of Smoking Cessation Medication Side Effects: A Genome-Wide Investigation of Abnormal Dreams on Varenicline. - Clinical pharmacology and therapeutics (2024) · Chenoweth MJ, Kim YJ, Nollen NL, Hawk LW, Mahoney MC, Lerman C, Knight J, Tyndale RF · PubMed 38369951
Varenicline, the most efficacious smoking cessation monotherapy, produces abnormal dreams. Although genetic contributions to varenicline-associated nausea and cessation have been identified, the role of genetics in abnormal dreams is unknown. We conducted a genomewide association study (GWAS) of abnormal dreams in 188 European ancestry smokers treated with varenicline (NCT01314001). Additive genetic models examined the likelihood of experiencing abnormal dreams 2 weeks following varenicline initiation. For the top locus, we tested for selectivity to varenicline, effects on cessation, replication, and generalizability to African ancestry (AA) individuals. The top GWAS variant associated with abnormal dreams was rs901886, mapping to intron 2 of ICAM5 on chromosome 19. The prevalence of abn
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Drug interactions
-
varenicline and abnormal dreams risk Moderate
rs10769203 G allele carriers have significantly elevated risk of abnormal dreams during varenicline-assisted smoking cessation
discuss side effect risk with prescriber before starting varenicline for smoking cessation